Final follow-up of a Phase I dose-ranging study of Bendamustine and Rituximab (BR) in patients with chronic lymphocytic leukemia (CLL) with comorbidities

被引：0
|
作者：
Danilov, Alexey [1 ]
Lewis, Lionel [2 ]
Brown, Jennifer [3 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Dartmouth Coll, Hanover, NH USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
LEUKEMIA & LYMPHOMA | 2017年 / 58卷
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
17
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [21] Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia
    Soumerai, Jacob D.
    Davids, Matthew S.
    Werner, Lillian
    Fisher, David C.
    Armand, Philippe
    Amrein, Philip C.
    Neuberg, Donna
    Hochberg, Ephraim P.
    Brown, Jennifer R.
    Abramson, Jeremy S.
    LEUKEMIA & LYMPHOMA, 2019, 60 (12) : 2931 - 2938
  • [22] IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY
    Fraser, G.
    Cramer, P.
    Demirkan, F.
    Santucci Silva, R.
    Grosicki, S.
    Janssens, A.
    Mayer, J.
    Dilhuydy, M. S.
    Pylypenko, H.
    Loscertales, J.
    Goy, A.
    Avigdor, A.
    Rule, S.
    Phelps, C.
    Mahler, M.
    Salman, M.
    Howes, A.
    Hallek, M.
    HAEMATOLOGICA, 2016, 101 : 150 - 151
  • [23] Bendamustine plus rituximab in untreated chronic lymphocytic leukemia patients. The MDA-CLL-2015-02 study
    De La Fuente, Adolfo
    Navas, Begona
    Gutierrez, Antonio
    Jose Terol, Maria
    Callejas, Marta
    Garcia Marco, Jose Antonio
    Dolores Garcia-Malo, Maria
    de la Serna, Javier
    Teresa Gonzalez-Gascon y Marin, Isabel
    Sanchis, Laura Garcia
    Ballesteros, Monia
    Benavente, Celina
    Jarque, Isidro
    Ochoa Gullon, Juliana
    Beneit, Paola
    de Ona, Raquel
    Montalabn, Carlos
    Estevez, Monica
    Iglesias, Rebeca
    Diaz-Lopez, Antonio
    Baltasar, Patricia
    LEUKEMIA & LYMPHOMA, 2017, 58 : 200 - 201
  • [24] Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND final results
    Welslau, M.
    Ghia, P.
    Pluta, A.
    Wach, M.
    Lysak, D.
    Kozak, T.
    Simkovic, M.
    Kaplan, P.
    Kraychok, I
    Illes, A.
    de la Serna, J.
    Dolan, S.
    Campbell, P.
    Musuraca, G.
    Jacob, A.
    Avery, E. J.
    Lee, J. H.
    Wang, D.
    Patel, P.
    Quah, C.
    Jurczak, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 71 - 72
  • [25] Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results
    Jacob, Abraham
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    De La Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Avery, Eric Joseph
    Lee, Jae Hoon
    Wang, Denise
    Patel, Priti
    Quah, Cheng Seok
    Jurczak, Wojciech
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 141 - 142
  • [26] Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group
    Bergmann, Manuela A.
    Goebeler, Maria E.
    Herold, Michael
    Emmerich, Bertold
    Wilhelm, Martin
    Ruelfs, Corinna
    Boening, Lothar
    Hallek, Michael J.
    HAEMATOLOGICA, 2005, 90 (10) : 1357 - 1364
  • [27] SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine plus Rituximab (BR) in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Tam, Constantine S.
    Giannopoulos, Krzysztof
    Jurczak, Wojciech
    Simkovic, Martin
    Shadman, Mazyar
    Osterborg, Anders
    Laurenti, Luca
    Walker, Patricia
    Opat, Stephen
    Chan, Henry
    Ciepluch, Hanna
    Greil, Richard
    Tani, Monica
    Trneny, Marek
    Brander, Danielle M.
    Flinn, Ian W.
    Grosicki, Sebastian
    Verner, Emma
    Brown, Jennifer R.
    Kahl, Brad S.
    Ghia, Paolo
    Tian, Tian
    Marimpietri, Carol
    Paik, Jason C.
    Cohen, Aileen
    Huang, Jane
    Robak, Tadeusz
    Hillmen, Peter
    BLOOD, 2021, 138
  • [28] SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine plus Rituximab (BR) in Patients With Treatment-Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Kahl, Brad S.
    Giannopoulos, Krzysztof
    Jurczak, Wojciech
    Simkovic, Martin
    Shadman, Mazyar
    Osterborg, Anders
    Laurenti, Luca
    Walker, Patricia
    Opat, Stephen
    Chan, Henry
    Ciepluch, Hanna
    Greil, Richard
    Tani, Monica
    Trneny, Marek
    Brander, Danielle M.
    Flinn, Ian W.
    Grosicki, Sebastian
    Verner, Emma
    Brown, Jennifer R.
    Ghia, Paolo
    Li, Jianyong
    Tian, Tian
    Zhou, Lei
    Marimpietri, Carol
    Paik, Jason C.
    Cohen, Aileen
    Robak, Tadeusz
    Hillmen, Peter
    Tam, Constantine S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S269 - S270
  • [29] Sequoia: Results of a randomized phase iii trial of zanubrutinib versus bendamustine plus rituximab (br) in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Greil, R.
    Robak, T.
    Giannopoulos, K.
    Jurczak, W.
    Simkovic, M.
    Shadman, M.
    Oesterborg, A.
    Laurenti, L.
    Walker, P.
    Opat, S.
    Chan, H.
    Ciepluch, H.
    Tani, M.
    Trneny, M.
    Brander, D. M.
    Flinn, I. W.
    Grosicki, S.
    Verner, E.
    Brown, J. R.
    Kahl, B. S.
    Ghia, P.
    Li, J.
    Tian, T.
    Zhou, L.
    Marimpietri, C.
    Paik, J. C.
    Cohen, A.
    Hillmen, P.
    Tam, C. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 117 - 118
  • [30] Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.
    Ruppert, Amy S.
    Mandrekar, Sumithra J.
    Booth, Allison M.
    Ding, Wei
    Bartlett, Nancy L.
    Brander, Danielle M.
    Coutre, Steve E.
    Brown, Jennifer R.
    Nattam, Sreenivasa R.
    Larson, Richard A.
    Erba, Harry Paul
    Litzow, Mark Robert
    Owen, Carolyn
    Kuzma, Charles S.
    Abramson, Jeremy S.
    Little, Richard F.
    Smith, Scott E.
    Stone, Richard M.
    Byrd, John C.
    Woyach, Jennifer Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345